|
LOC110806263
|
melanoma
|
0.100 |
GeneticVariation |
BEFREE |
TERT promoter mutations in cutaneous melanoma often show UV-signatures.
|
24260374 |
2013 |
|
LOC110806263
|
melanoma
|
0.100 |
GeneticVariation |
BEFREE |
TERT promoter mutations were identified in 154 (43%) of 362 successfully sequenced melanomas.
|
25217772 |
2014 |
|
LOC110806263
|
melanoma
|
0.100 |
GeneticVariation |
BEFREE |
TERT promoter mutations in sinonasal malignant melanoma: a study of 49 cases.
|
25746036 |
2015 |
|
LOC110806263
|
melanoma
|
0.100 |
GeneticVariation |
BEFREE |
TERT promoter mutations in melanoma render TERT expression dependent on MAPK pathway activation.
|
27449293 |
2016 |
|
LOC110806263
|
melanoma
|
0.100 |
GeneticVariation |
BEFREE |
TERT promoter mutations are frequent in melanoma.
|
29123258 |
2018 |
|
LOC110806263
|
melanoma
|
0.100 |
GeneticVariation |
BEFREE |
TERT promoter mutations were the most prevalent mutation type in PLA-positive melanomas; 82% of PLA-negative lesions had no mutations, and 97% of histopathologically confirmed melanomas were PLA and/or mutation positive (cohort 1, n = 103).
|
30500343 |
2019 |
|
LOC110806263
|
melanoma
|
0.100 |
GeneticVariation |
BEFREE |
A total of 77% of areas of intermediate lesions and melanomas in situ harbored TERT promoter mutations, a finding that indicates that these mutations are selected at an unexpectedly early stage of the neoplastic progression.
|
26559571 |
2015 |
|
LOC110806263
|
melanoma
|
0.100 |
GeneticVariation |
BEFREE |
Although TERT promoter mutations have been associated with a worsened prognosis in melanoma, the relationship between mutation status and downstream telomerase activity and telomere length remains convoluted.
|
31425705 |
2020 |
|
LOC110806263
|
melanoma
|
0.100 |
Biomarker |
BEFREE |
Although limited by sample size, our findings suggest that consideration be given to mutational analysis of metastatic tissue rather than the primary to guide BRAF-targeted therapy and question the roles of TERT promoter mutations and PD-L1 as predictive biomarkers in malignant melanoma.
|
30120967 |
2018 |
|
LOC110806263
|
melanoma
|
0.100 |
GeneticVariation |
BEFREE |
Because TERT promoter (TERT-p) mutations are common in inherently aggressive cutaneous conventional melanoma, we sought to evaluate their prognostic significance in spitzoid neoplasms.
|
26061100 |
2015 |
|
LOC110806263
|
melanoma
|
0.100 |
GeneticVariation |
BEFREE |
Coexistence of TERT promoter and BRAF mutations in cutaneous melanoma is associated with more clinicopathological features of aggressiveness.
|
26055532 |
2015 |
|
LOC110806263
|
melanoma
|
0.100 |
GeneticVariation |
BEFREE |
Comparing tumours situated on palms and soles with melanomas arising on dorsal acral sites, a higher frequency of NRAS (39.1% versus 25%) and NF1 (17.3% versus 0%) and lower frequencies of BRAF (21.7% versus 75%) and TERT promoter (8.6% versus 50%) mutations were observed.
|
31419753 |
2019 |
|
LOC110806263
|
melanoma
|
0.100 |
Biomarker |
BEFREE |
Distribution of BRAF mutations did not differ across multiple melanomas (P = 0.85), whereas TERT promoter changes decreased from first to subsequent melanomas (P = 0.04).
|
29061376 |
2018 |
|
LOC110806263
|
melanoma
|
0.100 |
GeneticVariation |
BEFREE |
Hence, combined targeting of RAS-ERK and TERT promoter remodeling is a promising avenue to limit long-term survival of a majority of melanomas that harbor these two mutations.
|
27911794 |
2016 |
|
LOC110806263
|
melanoma
|
0.100 |
Biomarker |
BEFREE |
Here we evaluated the detection of common mutations in BRAF, NRAS, and TERT promoter in 40 melanoma FFPE tissues using Droplet Digital (dd)PCR, and compared the results to the detection rates obtained by Sanger sequencing and pyrosequencing.
|
29305225 |
2018 |
|
LOC110806263
|
melanoma
|
0.100 |
GeneticVariation |
BEFREE |
Here we screen a panel of 115 melanoma tumor samples from Austrian patients to evaluate the prevalence and distribution of TERT promoter mutations.
|
27990595 |
2017 |
|
LOC110806263
|
melanoma
|
0.100 |
GeneticVariation |
BEFREE |
Here, we perform an unbiased proteome-wide survey of transcription factor binding at TERT promoter mutations in melanoma.
|
26553150 |
2016 |
|
LOC110806263
|
melanoma
|
0.100 |
GeneticVariation |
BEFREE |
Herein, we describe the use of combined bisulfite restriction enzyme analysis (COBRA) as a diagnostic tool for detecting the hypermethylated TERT promoter using in vitro methylated and unmethylated genomic DNA as well as genomic DNA from four melanomas and two benign melanocytic lesions.
|
28284778 |
2017 |
|
LOC110806263
|
melanoma
|
0.100 |
GeneticVariation |
BEFREE |
Highly recurrent TERT promoter mutations in human melanoma.
|
23348506 |
2013 |
|
LOC110806263
|
melanoma
|
0.100 |
GeneticVariation |
BEFREE |
In melanoma a correlation has been suggested between the occurrence of TERT promoter mutations and v-RAF murine sarcoma viral oncogene homolog B1 (BRAF) mutations.
|
25035100 |
2014 |
|
LOC110806263
|
melanoma
|
0.100 |
GeneticVariation |
BEFREE |
In particular, the high specificity of these mutations for melanoma indicates the presence of a TERT promoter mutation in a melanocytic neoplasm associated with diagnostic controversy, or uncertainty should increase concern for a melanoma.
|
30211730 |
2019 |
|
LOC110806263
|
melanoma
|
0.100 |
GeneticVariation |
BEFREE |
In this review we discuss the discovery and possible implications of the TERT promoter mutations in melanoma and other cancers.
|
24657534 |
2014 |
|
LOC110806263
|
melanoma
|
0.100 |
GeneticVariation |
BEFREE |
In this study, we aimed to assess the prognostic value of TERT promoter mutations in primary melanomas.
|
26875008 |
2016 |
|
LOC110806263
|
melanoma
|
0.100 |
GeneticVariation |
BEFREE |
Mutations of TERT promoter with UV signatures are frequent in conjunctival melanomas and favour a pathogenetic kinship with cutaneous melanomas.
|
23799844 |
2013 |
|
LOC110806263
|
melanoma
|
0.100 |
GeneticVariation |
BEFREE |
Mutations of the TERT promoter were not identified in conjunctival nevi or PAM without atypia, but were detected in 2/25 (8%) of PAM with atypia and 16/39 (41%) of conjunctival melanomas.
|
25159205 |
2014 |